01/22/2008
Teva to Acquire CoGenesys
Acquisition Will Bolster Teva's Biotechnology Capabilities
Cooley Godward Kronish represented CoGenesys in its M&A deal with Teva Pharmaceutical Industries Ltd. Team members included Partners Mike Lincoln, Kenneth Krisko, Bill Morrow, Michael Tuscan, David Walsh, Special Counsel Francis Fryscak, Associates Mark Hayman, Paul Laurence and Noah Pittard.
Jerusalem, Israel, January 22, 2008 – Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that it has entered into a definitive agreement to acquire CoGenesys, Inc., a privately-held biopharmaceutical company with a broad based biotechnology platform and focused on the development of peptide- and protein-based medicines across broad therapeutic categories. CoGenesys was established in 2005 as a division within Human Genome Sciences Inc. (HGSI) to focus on early drug development and was spun off as an independent company in June 2006.
For full press release, click here.